TITLE

Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010–2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010–2011 Influenza Season

AUTHOR(S)
Bateman, Allen C.; Kieke, Burney A.; Irving, Stephanie A.; Meece, Jennifer K.; Shay, David K.; Belongia, Edward A.
PUB. DATE
April 2013
SOURCE
Journal of Infectious Diseases;Apr2013, Vol. 207 Issue 8, p1262
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The 2009 influenza A virus subtype H1N1 (A[H1N1]pdm09) did not exhibit antigenic drift during the 2010–2011 influenza season, providing an opportunity to investigate the duration of protection after vaccination. We estimated the independent effects of 2010–2011 seasonal trivalent inactivated influenza vaccine (TIV) and A(H1N1)pdm09 vaccine for preventing medically attended influenza A virus infection during the 2010–2011 season.Methods. Individuals were tested for influenza A virus by real-time reverse transcription polymerase chain reaction (rRT-PCR) after a clinical encounter for acute respiratory illness. Case-control analyses compared participants with rRT-PCR–confirmed influenza A virus infection and test-negative controls. Vaccine effectiveness was estimated separately for monovalent pandemic vaccine and TIV and was calculated as 100 × [1 – adjusted odds ratio], where the odds ratio was adjusted for potential confounders.Results. The effectiveness of TIV against influenza A virus infection was 63% (95% confidence interval [CI], 37%–78%). The effectiveness of TIV against A(H1N1)pdm09 infection was 77% (95% CI, 44%–90%). Monovalent vaccine administered between October 2009 and April 2010 was not protective during the 2010–2011 season, with an effectiveness of −1% (95% CI, −146% to 59%) against A(H1N1)pdm09 infection.Conclusions. Monovalent vaccine provided no sustained protection against A(H1N1)pdm09 infection during the 2010–2011 season. This waning effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in A(H1N1)pdm09.
ACCESSION #
86428998

 

Related Articles

  • Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient. Abdo, Anselmo; Alfonso, Carlos; Diaz, Guillermo; Wilford, Mario; Rocha, Maykel; Verdecia, Niurka // Journal of Infection in Developing Countries;Feb2011, Vol. 5 Issue 2, p131 

    Conditions characterized by immunosuppression have been recently reported as risk factors for severe novel swine-origin influenza A (H1N1) virus (S-OIV) infection during the current 2009 pandemic. We report clinical and virological findings, antiviral therapy, and post- mortem study of S-OIV in...

  • Number of swine flu patients going into intensive care rises. Siva, Nayanah // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/7/2009, Vol. 339 Issue 7729, p1048 

    The article reports on the continued increase in the number of patients diagnosed with swine flu who were admitted to intensive care in England. For the week ended October 28, 2009, hospitalized patients with swine flu increased by 63 percent from July 2009. According to chief medical officer...

  • IN THE NEWS: DO WE NEED FLU SHOTS? J. P. // Baby Talk;Aug2010, Vol. 75 Issue 6, p48 

    The article presents the release of the universal recommendation from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices for adults on H1N1 flu virus, which means that the whole U.S. population are boosted to get vaccinated.

  • Influenza A virus vaccine H1N1.  // Reactions Weekly;9/4/2010, Issue 1317, p28 

    The article describes the case of a 52-year-old man with type 1 diabetes mellitus who was diagnosed with acute rejection after inoculation with influenza A virus vaccine H1N1.

  • Two seasons' experience with pandemic A H1N1 influenza infection in neonates. Martic, Jelena; Savic, Natasa; Jankovic, Borisav; Nedeljkovic, Jasminka; Rakonjac, Zorika; Pejic, Katarina; Markovic-Sovtic, Gordana // Turkish Journal of Pediatrics;Nov/Dec2012, Vol. 54 Issue 6, p612 

    There are only a few reports on influenza A H1N1 infection in neonates. In this paper, we present our additional experience on the clinical characteristics, epidemiology and treatment of influenza A H1N1 (2009) infection in 10 newborn infants (aged 9-24 days). Influenza A H1N1 infection was...

  • Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination Ioannidis, John P. A.; Manzoli, Lamberto; De Vito, Corrado; D'Addario, Maddalena; Villari, Paolo // PLoS Clinical Trials;Dec2011, Vol. 6 Issue 12, p1 

    Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among...

  • Characteristics of Patients Hospitalized with 2009 H1N1 Influenza in a Tertiary Care Hospital in Southern Saudi Arabia. Agha, Adnan; Alrawi, Abdulqader; Munayco, Cesar V.; AlAyed, Mohammed S.; Al-Hakami, Mohammad; Korairi, Hassan; Bella, Abdelhaleem // Mediterranean Journal of Hematology & Infectious Diseases;2012, Vol. 4 Issue 1, p1 

    Background: Pandemic influenza A (H1N1) virus emerged and spread globally in the spring of 2009. We describe the clinical features of the patients who were hospitalized with 2009 H1N1 influenza July 2009 to June 2010 in a tertiary care hospital in Khamis Mushyt, Saudi Arabia. We analyzed the...

  • Gene Constellation of Influenza A Virus Reassortants with High Growth Phenotype Prepared as Seed Candidates for Vaccine Production. Fulvini, Andrew A.; Ramanunninair, Manojkumar; Le, Jianhua; Pokorny, Barbara A.; Arroyo, Jennifer Minieri; Silverman, Jeanmarie; Devis, Rene; Bucher, Doris // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Background: Influenza A virus vaccines undergo yearly reformulations due to the antigenic variability of the virus caused by antigenic drift and shift. It is critical to the vaccine manufacturing process to obtain influenza A seed virus that is antigenically identical to circulating wild type...

  • Public health, pharmacy joining forces for community health. Krisberg, Kim // Nation's Health;Oct2014, Vol. 44 Issue 8, p1 

    The article reports on the partnership between the Florida Department of Health in Palm Beach and local pharmacies in the state to create the Cities Readiness Initiative in response to the H1N1 pandemic in 2009. Topics discussed include the distribution of around 40,000 doses of H1N1 flu vaccine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics